Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Overview of attention for article published in Frontiers in Neurology, January 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 1 X post from an account with 10,425 followers.

New Research: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Objective To assess the pharmacokinetics and pharmacodynamics of… https://t.c

01 Feb 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.